Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lee’s Pharma Obtains China Rights to Therapeutic Peptide from RegeneRx

publication date: Jul 16, 2012
Lee’s Pharmaceutical of Hong Kong has bought the China rights to a novel clinical-stage peptide from RegeneRx Biopharma. Thymosin beta 4 (Tβ4) is being developed by for tissue and organ protection, repair and regeneration. Its three formulations target very different indications: dry eye, cardiovascular/nervous system disorders, and skin disease/chronic wounds. More details....

Stock Symbols: (HK: 950) (OTCBB: RGRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital